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90Objective: Cardiac reoperations have been associated with increased morbidity and mortality compared with
first-time surgery. We analyzed our experience with reoperative aortic valve replacement (redo-AVR) and
compared these results with those from patients who had undergone transapical aortic valve implantation
(TA-AVI) as a second heart operation.
Methods: In the present retrospective observational comparative study, we analyzed the outcome of 136 patients
with previous cardiac surgery who had undergone conventional redo-AVR (n ¼ 59; since 2006) or TA-AVI
(n ¼ 77; since 2008) with respect to the 30-day outcomes (Valve Academic Research Consortium criteria),
1- and 3-year survival, and the risk factors for both approaches after previous heart surgery.
Results: Neither group differed significantly in their risk profile, leading to similar Society of Thoracic Surgeon
score and EuroSCORE. The 30-day mortality was 3.39% (n¼ 2) in the redo-AVR group and 7.8% (n¼ 6) in the
redo TA-AVI group (P¼ .465). The overall combined safety endpoint at 30 days was significantly lower for the
TA-AVI patients (18.1% vs 33.9% in redo-AVR; P¼ .036). The unadjusted and adjusted 1-year survival showed
no difference between the 2 groups. The unadjusted 3-year survival revealed a 2.1-fold greater mortality risk
after TA-AVI (P ¼ .055). Adjustment by multivariate Cox regression analysis (hazard ratio, 1.427; 95% confi-
dence interval, 0.635-3.209; P ¼ .389) and propensity score (hazard ratio, 1.571; 95% confidence interval,
0.575-4.291; P ¼ .378) led to a>50% risk reduction, resulting in similar 3-year survival in the 2 groups.
Conclusions: Redo-AVR can be performed with acceptable results in high-risk patients and still serves as the
reference standard. Reoperative valve surgery by TA-AVI is feasible and results in comparable short- and
mid-term survival. (J Thorac Cardiovasc Surg 2014;148:90-7)Earn CME credits at
http://jtcvs.com/cme/home
The increasing age in the western population and the ad-
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The Journal of Thoracic and Cardiovascular Surgetechniques, this surgical approach features several technical
challenges. The re-entry risk, including injuries to grafts, and
the method of achieving sufficient myocardial protection are
challenging.1 Also, the advanced cardiovascular morbidity
of most of the mostly elderly patients undergoing repeat sur-
gery aggravates the perioperative risk. Therefore, cardiac re-
operations have been associated with increased morbidity
and mortality compared with first-time surgery.2 The intro-
duction of transcatheter aortic valve implantation (ie, trans-
femoral [TF-AVI], transapical [TA-AVI], transaortic, trans-
subclavian) represents a promising alternative for aortic
valve interventions in high-risk patients. However, data on
the outcome for TAVI after previous cardiac surgery
compared with conventional redo-AVR are still limited.
Moreover, previous studies have either focused on mixed
treatment groups (TF-AVI and TA-AVI), have specifically
compared the outcomes after previous coronary artery
bypass grafting,3,4 or have compared TA-AVI after previous
cardiac surgery with TA-AVI as the first procedure.5,6
In this context, we retrospectively analyzed the outcome
of redo-AVR and compared the results with the outcomes of
patients who had undergone TA-AVI as a secondary cardiacry c July 2014
TABLE 1. Patient demographics and preoperative characteristics
Variable
Redo-AVR
(n ¼ 59)
TA-AVI
(n ¼ 77)
P
value
Male gender 39 (66.1) 46 (59.7) .479*
Age (y) 66.75  16.95 79.51  6.29 <.001y
BMI (kg/m2) 26.86  4.52 26.58  4.79 .729y
STS score (%) 9.94  3.25 11.23  4.25 .216y
EuroSCORE, numeric 10.54  2.91 11.49  2.99 .068y
EuroSCORE, logistic
Median 20.68 24.99 .134z
IQR 12.35-35.55 14.55-41.65
Preoperative LVEF (%) 53.69  13.38 52.17  14.11 .533y
AF 14 (23.7) 16 (20.8) .683*
NYHA class III-IV 45 (76.3) 65 (86.7) .173*
COPD 6 (10.2) 9 (11.7) 1*
CAD 33 (55.9) 70 (90.9) <.001*
PAOD 9 (15.3) 25 (32.5) .028*
Renal dysfunction 29 (49.2) 45 (58.4) .302*
PH 20 (33.9) 27 (35.1) 1*
Preoperative creatinine (mg/dL)
Mean 1.09 1.22 .106z
Range 0.88-1.39 0.98-1.59
Diabetes 17 (28.8) 31 (40.3) .206*
Data presented as n (%) or mean standard deviation, unless otherwise noted. Renal
dysfunction considered present if preoperative serum creatinine>1.1 mg/dL. AVR,
Aortic valve replacement; TA-AVI, transapical aortic valve implantation; BMI, body
mass index; STS, Society of Thoracic Surgeons; IQR, interquartile range; LVEF,
left ventricular ejection fraction; AF, atrial fibrillation; NYHA, New York Heart Asso-
ciation; COPD, chronic obstructive pulmonary disease; CAD, coronary artery dis-
ease; PAOD, peripheral arterial occlusive disease; PH, pulmonary hypertension
(>50 mm Hg systolic pressure). *Fisher’s exact test. yStudent’s t test. zWilcoxon
rank sum test.
Abbreviations and Acronyms
AI ¼ aortic insufficiency
AVR ¼ aortic valve replacement
CIs ¼ confidence intervals
HRs ¼ hazard ratios
TA-AVI ¼ transapical aortic valve implantation
TF-AVI ¼ transfemoral aortic valve implantation
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comes (Valve Academic Research Consortium [VARC]
criteria), 1- and 3-year survival, and the risk factors for
both approaches.
METHODS
Data Collection
We queried our institutional adult cardiac surgery database for all pa-
tients who had undergone isolated redo-AVR at our institution from
January 2006 to May 2011. Reoperative surgery was defined as any previ-
ous cardiac operation using a thoracotomy or sternotomy approach. In
addition, we scanned our database for all patients who had undergone
TA-AVI (February 2008 to April 2012). Patients with endocarditis and
emergency cases were excluded from the analysis. The review of our data-
bases identified 136 patients with previous cardiac surgery who had under-
gone conventional redo-AVR (n ¼ 59) or TA-AVI (n ¼ 77). The patient
demographics and preoperative characteristics are listed in Table 1. The
previous cardiac operations are listed in Table 2. All patients underwent
redo aortic valve surgery for either aortic stenosis or insufficiency. From
January 2006 to February 2008, redo-AVRwas the only available treatment
option, because the TA treatment approach was first introduced at our insti-
tution in February 2008. All patients accepted for TA-AVI were selected by
the heart team of our institution. TF-AVI was considered as the first option,
and TA-AVI was used in the case of contraindications for TF-AVI. A total
of 37 patients who had undergone redo-AVR underwent surgery before the
start of our TA-AVI program, and 22 had undergone redo-AVR, despite the
existing transcatheter treatment option.
The local ethics committee approved the present study.
Prosthetic Valve System and Procedure
Conventional redo-AVR. The specific details of the surgical tech-
nique, valve selection, and implantation were determined by the individual
cardiac surgeon. In general, the patients had undergone redo median ster-
notomy and establishment of cardiopulmonary bypass by way of the
ascending aorta and right atrium. The types of prosthesis used were the
Carpentier-Perimount (Edwards LifeSciences, Irvine, Calif), Mitroflow,
and Carbomedics (both Sorin, Milano, Italy).
Redo TA-AVI. TA-AVI was performed using the Edwards SAPIEN
prosthesis (Edwards LifeSciences). The procedural steps were performed
as previously described.7
Endpoints
The objective of the present study was (1) to analyze the potential
differences between redo-AVR and TA-AVI regarding the 30-day outcomes
(VARC criteria)8; (2) to estimate the effect of the type of surgical procedure
on 1- and 3-year survival; and (3) to identify the potential risk factors for
mortality for each surgical procedure.
Statistical Analysis
We used unpaired t tests for parametric variables, Mann-WhitneyU tests
for nonparametric variables, andFisher’s exact tests for categorical variablesThe Journal of Thoracic and Cto perform pairwise comparisons for the pre-, peri-, and postoperative fac-
tors. The effect of the type of surgical procedure on 1- and 3-year survival
was analyzed using 3 different methods. First, a univariate Cox regression
model was fitted to estimate the unadjusted treatment effect of TA-AVI
versus redo-AVR. Additionally, the survival curves were estimated using
the Kaplan-Meier method and compared using the log-rank test. Second,
an adjusted treatment effect was estimated within a Cox regression model
that included the clinically relevant covariates with P<.1 on univariate Cox
regression analysis and remaining in the model after backward, stepwise
selection. The variables considered are listed in Tables 1 and 2, plus the
log creatinine. Third, a propensity score-based analysis was performed to
validate the estimated treatment effect. The propensity score was estimated
using a logistic regression model, with the type of surgery as an outcome
and the preoperative patient characteristics as covariates, and then included
in a Cox regression model to evaluate the propensity score-adjusted treat-
ment effect. Univariate Cox regression models were fitted for each surgical
procedure to identify the predictors for 1- and 3-year mortality.
For Cox regression models, hazard ratios (HRs) for the comparison be-
tween TA-AVI and redo-AVR, the corresponding 95% confidence intervals
(CIs), and the results of the Wald test of the hypothesis of a no-treatment
effect are reported. All reported P values are 2-sided, and P< .05 was
considered statistically significant. Statistical analysis was performed us-
ing Excel (Microsoft, Redmond, Wash) and SPSS (IBM, Somers, NY).RESULTS
Preoperative Clinical Characteristics
Apart fromage, coronaryheart disease, andperipheral arte-
rial occlusive disease, the compared groups did not differardiovascular Surgery c Volume 148, Number 1 91
TABLE 2. Details of previous cardiac surgery in both groups
Previous cardiac surgery
Redo-AVR
(n ¼ 59)
TA-AVI
(n ¼ 77)
P
value
Isolated cardiac surgery 39 (66.1) 74 (96.1) <.001
AVR 11 (18.6) 4 (5.1) .013
AVR (biologic) 6 (10.2) 4 (5.1) .271
AVR (mechanical) 5 (8.5) 0 (0) .009
CABG 23 (39.0) 67 (87.0) <.001
MVR 5 (8.5) 3 (3.8) .261
Combined cardiac surgery 12 (20.3) 3 (3.8) .002
CABG/AVR 6 (10.2) 2 (2.5) .063
CABG/MVR 3 (5.1) 1 (1.2) .195
CABG/other valve 1 (1.7) 0 (0) .252
AVR/MVR 2 (3.4) 0 (0) .104
Other* 8 (13.6) 0 (0) <.001
Data presented as n (%). AVR, Aortic valve replacement; TA-AVI, transapical aortic
valve implantation; CABG, coronary artery bypass grafting; MVR, mitral valve
replacement. *Included surgery for aneurysm of the ascending aorta (n ¼ 3), David
procedure (n¼ 1), mitral valve reconstruction (n¼ 2), andmitral valve reconstruction
plus tricuspid valve reconstruction (n ¼ 2).
TABLE 3. Preoperative and postoperative echocardiographic
characteristics
Variable Redo-AVR TA-AVI P value
Preoperative
EF (%) 53.69  13.38 52.17  14.11 .533*
EF>50% 40 (67.8) 49 (63.6) .613y
EF 30-50% 15 (25.4) 24 (31.1) .463y
EF<30% 4 (6.8) 4 (5.1) .697y
Pmax 69.86  25.92 72.03  25.30 .669*
Pmean 44.73  18.48 45.72  19.24 .790*
Vmax 4.04  0.84 5.04  5.90 .224*
Postoperative
EF (%) 54.41  10.37 51.98  12.11 .285
Pmax 23.79  14.16 20.17  9.84 .135*
Pmean 13.18  8.78 11.00  5.58 .147*
Vmax 2.31  0.61 2.27  1.03 .797*
Data presented as mean  standard deviation or n (%). AVR, Aortic valve
replacement; TA-AVI, transapical aortic valve implantation; EF, ejection fraction;
Pmax, transaortic valve peak gradient; Pmean, transaortic valve mean gradient;
Vmax, maximum transvalvular blood flow velocity. *Student’s t test. yFisher’s
exact test.
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acteristics (Table 1). The TA-AVI patients had more
frequently undergone previous isolated cardiac surgery, in
particular, coronary artery bypass grafting (Table 2), and
the redo-AVR patients were more likely to have undergone
combined cardiac surgery.
Perioperative Characteristics and 30-Day Outcomes
The 30-day mortality did not differ between the redo-AVR
and TA-AVI patients. The overall combined safety endpoint
at 30 days8 was significantly lower in the TA-AVI patients.
This had mainly resulted from the significant differences in
disabling bleeding complications. Consistently, patients in
the redo-AVR group had a significantly greater median blood
loss and significantly greater transfusion requirements. Acute
kidney injury was the most frequent complication, followed
by bleeding complications, third-degree atrioventricular
block, and strokeor transient ischemic attack.Adetailed anal-
ysis of the in-hospital cardiovascular and noncardiovascular
complications, and prosthetic valve associated-, therapy
specific-, and echocardiographic outcomes according to the
VARC criteria is provided in Tables 3 and 4. Moreover, the
analysis showed a significant difference in the duration of
mechanical ventilation, although this difference did not
influence additional pulmonary complications such as
pneumonia, the incidence of reintubation, or the need for
tracheostomy. Eight patients died before hospital discharge
(2 in the redo-AVR group and 6 in the TA-AVI group); there-
fore, 57 patients in the redo-AVR group and 71 patients in the
TA-AVI group were eligible for the analysis of the length of
stay. The 2 groups did not differ with regard to the median
intensive care unit stay, although the total hospital stay for
the redo-AVRpatientswas slightly longer (Table 5).Nomajor
sternal wound infections or mediastinitis were observed in
our patients.92 The Journal of Thoracic and Cardiovascular SurgeEffect of Surgery Type on 1- and 3-Year Survival
The mean follow-up was 7.7 months (range, 1-36.6) in
the TA-AVI group and 25.3 months (range, 1-59.6) in the
redo-AVR group. Survival after 1 year was 86.4% in the
redo-AVR group and 81.8% in the redo TA-AVI group,
for an unadjusted HR of 1.613 (95% CI, 0.673-3.871;
P ¼ .284; Fig. 1, A).
After the initial univariate Cox regression analysis and
a stepwise elimination procedure (likelihood method),
removing nonsignificant variables from the initial multi-
variate Cox regression model, the HR for TA-AVI versus
redo-AVR was estimated as 1.089 (95% CI, 0.431-2.754;
P ¼ .857), adjusted for the numeric EuroSCORE and
renal insufficiency (Figure 1, B). We also performed a
propensity score-based analysis to validate the results of
the multivariate Cox regression model. From a Cox
regression analysis that included the treatment indication
and propensity score, the HR for TA-AVI versus redo-
AVR was estimated as 1.655 (95% CI, 0.485-5.642;
P ¼ .421; Figure 1, C).
The unadjusted cumulative survival after 3 years showed
a trend toward lower survival for the TA-AVI patients than
for the redo-AVR patients (75.9% vs 54.6%; estimated HR,
2.122; 95% CI, 0.971-4.637; P ¼ .055; Figure 1, D). Using
the multivariate Cox regression model, the HR for TA-AVI
versus redo-AVR was estimated as 1.427 (95% CI, 0.635-
3.209; P ¼ .389), adjusted for the numeric EuroSCORE
and renal insufficiency (Figure 1, E). From a Cox regression
analysis that included the treatment indication and propen-
sity score, the HR for TA-AVI versus redo-AVR was
estimated as 1.571 (95% CI, 0.575-4.291; P ¼ .378;
Figure 1, F). For easier comparison, the HRs and corre-
sponding 95% CIs are listed in Table 6.ry c July 2014
TABLE 4. 30-Day outcomes according to VARC criteria
Variable
Redo-AVR
(n ¼ 59)
TA-AVI
(n ¼ 77)
P
value
All-cause mortality (30 d) 2 (3.39) 6 (7.8) .465
Cardiovascular mortality (30 d) 1 (1.69) 3 (3.8) .451
Valve-related mortality (30 d) 0 (0) 1 (1.3)* .380
Myocardial infarction 0 (0) 0 (0) —
Stroke
Major 0 (0) 1 (1.3) .380
Minor 0 (0) 0 (0) —
Transitory ischemic attack 1 (1.69) 1 (1.3) .849
Bleeding complications
Life threatening/disabling 7 (11.8) 0 (0) .002
Major 2 (3.4) 2 (2.6) .786
Minor 1 (1.7) 1 (1.3) .849
Vascular complications
Major 0 (0) 1 (1.3) .380
Minor 0 (0) 2 (2.6) .212
Noncardiovascular complications
AKIy 22 (37.3) 30 (38.9) .842
Stage 1 7 (11.9) 16 (20.8) .169
Stage 2 4 (6.8) 7 (9.1) .642
Stage 3 11 (18.6) 7 (9.1) .103
Combined safety endpoint (at 30 d)z 20 (33.9) 14 (18.1) .036
Prosthetic valve-associated endpoints
New left bundle branch block 1 (1.7) 1 (1.3) .842
New atrioventricular block, third degree 6 (10.1) 3 (3.9) .145
New permanent pacemaker implantation 6 (10.1) 3 (3.9) .145
Worsening mitral valve regurgitation 0 (0) 1 (1.3) .380
Worsening mitral valve stenosis 0 (0) 0 (0) —
Coronary obstruction 0 (0) 0 (0) —
Therapy-specific endpoints —
Valve-in-valve implantation (unplanned) 0 (0) 2 (2.6)
Cardiopulmonary bypass use (unplanned) 0 (0) 4 (5.2)
Conversion to conventional AVR 0 (0) 1 (1.3)*
Echocardiography
Aortic regurgitation
Grade 0 59 (100) 19 (24.7) <.001
Grade I 0 (0) 50 (64.9) <.001
Grade II 0 (0) 8 (10.3) .011
Grade III-IV 0 (0) 0 (0) —
Data presented as n (%). AVR, Aortic valve replacement; TA-AVI, transapical aortic
valve implantation; AKI, acute kidney injury; VARC, Valve Academic Research Con-
sortium. *Need for conversion due to valve dislocation; patients data and outcome
was analyzed in the TA-AVI group. yEight patients with preprocedural hemodialysis
were excluded from the analysis of AKI. zComposite of all-cause mortality, major
stroke, life-threatening bleeding, AKI stage 3, myocardial infarction, and repeat pro-
cedure for valve-related dysfunction.
TABLE 5. Additional peri- and postprocedural characteristics
Variable Redo-AVR TA-AVI P value
OR duration (min) 216  53 109  35 .001*
Chest drainage 1
POD (mL)
545 (345-870) 307 (170-410) <.001y
Chest drainage total (mL) 990 (660-1650) 540 (340-870) <.001y
Rethoracotomyz 7 (11.9) 1 (1.3) .021x
RBC transfusion (U) 4 (3-8) 2 (0-3) <.001y
FFP transfusion (U) 4 (2-6) 0 <.001y
Platelet transfusion (U) 1 (0-2) 0 <.001y
Artificial respiration
time (h)
20.41 (16.25-32.41) 13.25 (9.15-17.3) <.001y
Reintubation 7 (11.9%) 2 (2.6%) .031x
Tracheotomy 5 (8.5%) 0 (-) .009x
Dialysis postoperatively 9 (15.3%) 7 (9.1%) .269x
ICU stay (d) 2.5 (1-7) 4 (2-6) .522y
In-hospital stay (d) 13.5 (11-16) 12 (9-14) .033y
Data presented as mean standard deviation, median (interquartile range), or n (%).
AVR, Aortic valve replacement; TA-AVI, transapical aortic valve implantation; OR,
operating room; POD, postoperative day; RBC, red blood cell; FFP, fresh frozen
plasma; ICU, intensive care unit. *Student’s t test. yWilcoxon rank sum test.
zRethoracotomy after redo-AVR was for bleeding complications in all cases; rethor-
acotomy after TA-AVI was for valve dislocation and conversion to conventional AVR.
xFisher’s exact test.
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Group
The univariate logistic regression analysis for 1- and
3-year survival revealed almost the same results. The numeric
and logistic EuroSCORE, preoperative renal dysfunction,
postoperative acute kidney injury, acute kidney injury stage
III, and artificial respiration time>24 hours were indepen-
dent significant predictors for diminished 1- and 3-year sur-
vival in the redo-AVR group.The Journal of Thoracic and CIn contrast, the numeric and logistic EuroSCORE and
transfusion of>6 red blood cell units were identified as
risk factors for diminished 1- and 3-year survival in the
TA-AVI group. Additionally, a left ventricular ejection frac-
tion<50% showed a significant associationwith diminished
3-year survival in the TA-AVI group (a detailed overview is
shown in Figure 2). Considering the whole cohort of pa-
tients, age appeared as a predictor for diminished 3-year sur-
vival (HR, 1.059; P ¼ .025) but the type of previously
performed cardiac surgery did not (previous AVR, HR,
0.589; 95% CI, 0.225-1.542; P ¼ .281; previous coronary
artery bypass grafting, HR, 1.094; 95% CI, 0.508-2.359;
P ¼ .818; other type of previous surgery, HR, 0.770; 95%
CI, 0.311-1.403; P ¼ .571). Postoperative aortic insuffi-
ciency after TA-AVI did not appear as a risk factor for dimin-
ished 1-year (HR, 1.35; 95% CI, 0.87-1.65; P ¼ .597) or
3-year (HR, 1.24; 95% CI, 1.1-1.85; P ¼ .359) survival.
In summary, our data have shown that the 30-day out-
comes did not differ in the 2 groups, except for greater blood
loss and transfusion requirements after redo-AVR, leading
to a significantly greater combined safety endpoint in these
patients. The TA-AVI group had a significantly shorter dura-
tion ofmechanical ventilation and a reduced in-hospital stay.
The 1-year survival did not differ between the 2 groups, in
either the unadjusted or adjusted models. After multivariate
Cox regression analysis and propensity scoring, the trend to-
ward lower 3-year survival in the TA-AVI patients could not
be confirmed.
DISCUSSION
Previous cardiac surgical intervention carries a signifi-
cantly greater perioperative risk and therefore has oftenardiovascular Surgery c Volume 148, Number 1 93
FIGURE 1. Survival curves for A-C, 1-year and D-F, 3-year survival. AVR, Aortic valve replacement; TA-AVI, transapical aortic valve implantation.
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for alternative therapies.9 The apprehensions concerning
redo surgery are (to some extent) science based, because
the operative mortality associated with redo cardiac surgery
has been greater higher than that for the initial opera-
tion.10,11 However, Maganti and colleagues12 showed, in a
retrospective study, that the 5-year survival of elderly
patients after reoperative AVR is likely greater than the ex-
pected survival without surgical intervention.
TAVI has been developed to face the problem of ‘‘high-
risk patients’’ with symptomatic aortic stenosis who also
have significant comorbidities or present with contraindica-
tions to conventional surgery.13 Because a reasonable94 The Journal of Thoracic and Cardiovascular Surgenumber of patients referred for TAVI present with contrain-
dications for TF-AVI, TA-AVI currently represents the most
established approach for these patients. In this context and
because TA-AVI is generally considered more invasive
than TF-AVI owing to the thoracotomy, puncture and/or
suture on the left ventricular apex, and the necessity for
general anesthesia, we compared the outcomes after con-
ventional AVR and TA-AVI after previous cardiac surgery
to analyze the perioperative morbidity and mortality and
1- and 3-year survival and identify the risk factors contrib-
uting to the 1- and 3-year mortality.
First, our study showed that reoperative conventional
AVR can be performed safely and successfully, especiallyry c July 2014
TABLE 6. Effect of treatment with TA-AVI vs redo-AVR on 1- and
3-year survival
Variable HR 95% CI P value*
1-y Survival
Univariate analysisy 1.613 0.673-3.871 .284
Multivariate Cox regression analysisz 1.089 0.431-2.754 .857
Propensity score-based analysisx 1.655 0.485-5.642 .421
3-y Survival
Univariate analysisy 2.122 0.971-4.637 .059
Multivariate Cox regression analysisz 1.427 0.635-3.209 .389
Propensity score-based analysisx 1.571 0.575-4.291 .378
Variables entered in the univariate and propensity score-based analysis included age
(y), male gender, BMI>30 kg/m2, numeric and logistic EuroSCORE, Society of
Thoracic Surgeons score, left ventricular ejection fraction  50%, coronary artery
disease, NYHA class III-IV, hypertension, diabetes mellitus, chronic obstructive pul-
monary disease, peripheral occlusive disease, renal insufficiency (serum creatinine
>1.1 mg/dL), log (creatinine) (mg/dL), nicotine abuse, atrial fibrillation, previous
CABG, previous AVR, previous AVR plus CABG, and other types of previous cardiac
surgery. TA-AVI, Transapical aortic valve implantation; AVR, aortic valve replace-
ment; HR, hazard ratio; CI, confidence interval; BMI, body mass index; NYHA,
New York Heart Association; CABG, coronary artery bypass grafting. *Two-sided
Wald test in a Cox regression model. yCox regression model, including a treatment
indicator. zCox regression model, including a treatment indicator, and adjusted for
numeric EuroSCORE and preoperative renal insufficiency. xCox regression model,
including a treatment indicator, and adjusted for propensity score.
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the published data have indicated a broad range of reported
operativemortality rates for patients undergoing reoperation
for AVR of 2.3% to 17.6%,14,15 a continuous trend has been
seen toward lower short-term mortality rates. Consistent
with our observation, Jones and colleagues11 reported a hos-
pital mortality of 6.4% for reoperative AVR in a cohort of
671 patients with a mean age of 55 years, even lower than
in our study. The 1-year survival in our series was accept-
able, with a survival rate of 86%, and compared favorably
with that reported by Balsam and colleagues,16 who found
a 1-year survival after reoperative valve surgery of 84%.
Few studies have focused on the outcomes of TA-AVI af-
ter previous heart surgery. Walther and colleagues6 pre-
sented an in-hospital mortality rate of 12% and an overall
1-year survival of 72% for 25 patients who had undergone
TA-AVI as a redo procedure. These results are consistent
with those from our study, showing a 30-day mortality of
7.8% and a 1-year mortality of 18.2%. Similarly, Drews
and colleagues17 reported a 30-day mortality of 6.9% and
a 1-year survival of 74% in a 40-patient cohort of high-
risk patients who had undergone TA-AVI as a redo proce-
dure. D’Onofrio and colleagues5 reported the results from
the Italian registry of TA-AVI and analyzed the outcomes
of 110 patients after TA-AVI as a cardiac reoperation.
They reported a 30-daymortality of 7.9%, with a 1-year sur-
vival of 82.7%, leading the investigators to conclude that
high-risk patients with previous cardiac surgery requiring
AVR are potential candidates for TA-AVI. From a technical
viewpoint our results support this hypothesis: the apex for
transapical access could be exposed without complication,The Journal of Thoracic and Cand valve implantation was performed directly through the
pericardium in all caseswithout incident.However, in agree-
ment with our colleagues, a distinct disadvantage was that
the left anterior descending artery could not be visualized
when choosing the appropriate implantation site.17 Howev-
er, the presence of coronary artery bypass grafts allows the
cardiac surgeon to exclusively concentrate on implantation
of the valve in the perfect landing zone, without the risk of
occluding the coronary ostia.
Comparison of Redo-AVR and TA-AVI
Although our analysis revealed a significantly reduced
operation time, less transfusion of blood products, reduced
ventilation time, and a shorter in-hospital stay for the TAVI-
patients, this did not translate to a significant reduction in
the in-hospital or 1-year mortality. The observed difference
in terms of the reduced combined safety endpoint (VARC
criteria) was almost exclusively caused by the difference
in disabling bleeding complications. The unadjusted and
adjusted 1-year survival showed no difference between
the 2 groups. In contrast, analysis of the unadjusted
3-year survival was (as expected) influenced by age and re-
vealed a 2.1-fold greater mortality risk after TA-AVI.
Although the observed difference did not reach statistical
significance (P ¼ .055), this trend became even more
obvious on the Kaplan-Meier curve (Figure 1, D). Because
a simple overall comparison of the results from nonrandom-
ized observational studies could lead to a biased estimate of
the analyzed effect, we included a multiple regression
model and a propensity score-based analysis as additional
statistical approaches to rule out possible confounding.
Remembering that patients accepted for TA-AVI were indi-
vidually classified by an interdisciplinary heart team as
high-risk patients, unquestionable bias was present when
comparing both groups. These differences did not become
apparent significantly, when focusing on the commonly
accepted preoperative characteristics (in particular, the So-
ciety of Thoracic Surgeons score and EuroSCORE) as listed
in Table 1. The 2 groups did differ with regard to the type of
previously performed surgery. However, statistical adjust-
ment using multivariate Cox regression analysis and pro-
pensity score matching led to similar 3-year survival in
the 2 groups, and the type of previously performed proce-
dure showed no statistical influence on outcome or survival.
These facts again underline the necessity of developing
more accurate risk scores. In addition, our analysis did
not identify aortic insufficiency (AI) after TA-AVI as a pre-
dictor of mortality after TAAVI. This finding is in contrast
to those from several studies showing that postprocedural
AI impairs patient outcomes after TAVI.18 This could, at
least in part, be explained by the relatively small patient
number showing AI grade II and the absence of severe AI
in our patients. However, the causal relationship between
AI and increased mortality remains to be clarified.ardiovascular Surgery c Volume 148, Number 1 95
FIGURE 2. Univariate analysis for diminished (A) 1-year and (B) 3-year survival after conventional redo-aortic valve replacement (AVR) and transapical
aortic valve implantation (TA-AVI). No statistically significant influencewas found for age, gender, pulmonary hypertension, left ventricular ejection fraction
(LVEF)<50%, chronic obstructive pulmonary disease, hypertension, diabetes, peripheral arterial occlusive disease, atrial fibrillation, smoking, bleeding
postoperatively, red blood cell (RBC) transfusion>4 U, type of previously performed surgery, or postprocedural aortic insufficiency. Black line, redo-
AVR; dotted line, TA-AVI. Renal dysfunction preoperatively was defined by serum creatinine>1.1 mg/dL. HR, Hazard ratio; CI, confidence interval;
STS, Society of Thoracic Surgeons; AKI, acute kidney injury.
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The present study was a post hoc nonprespecified anal-
ysis, and we could not rule out the possibility that other po-
tential confounding variables not included in the studymight
have affected the results. Our findings were based on a small
sample size and clinical events from a single site, limiting
the generalizability. Moreover, the patients after conven-
tional redo AVR presented with a different profile regarding
the previous cardiac surgery than did the TA-AVI patients,
although we tried to rule out possible confounders by statis-
tical adjustment, and the different types of previously per-
formed cardiac surgery did not appear as a risk factor.
In conclusion, conventional redo-AVR can be performed
with acceptable results in this specific patient population.
At present, however, no randomized clinical trial data
comparing conventional and transcatheter treatment options
are available. As these techniques continue to develop,
analyses such as ours will serve as landmarks, as long as
randomized trials comparing these new strategies with
conventional AVR are missing. Reoperative isolated valve
surgery using TA-AVI is feasible, has an acceptable risk pro-
file, and results in short- and mid-term survival comparable
to that for patients after conventional redo-AVR and, there-
fore, is a viable alternative for selected high-risk patients.
However, our analysis did not provide any evidence showing
that conventional redo-AVR should not be considered the
reference standard for AVR after previous cardiac surgery.References
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